https://pepsreview.com/articles/lillys-foundayo-six-months-first-non-peptide-glp-1-pill PepsReview en 2026-10-11 Foundayo, orforglipron, Eli Lilly, GLP-1 pill, oral GLP-1, non-peptide agonist, weight loss drug, FDA approval https://pepsreview.com/articles/novo-nordisk-amycretin-phase-2-diabetes-weight-loss PepsReview en 2026-10-11 amycretin, zenagamtide, Novo Nordisk, GLP-1, amylin, type 2 diabetes, weight loss drug, clinical trial https://pepsreview.com/articles/glp-1-injury-claims-data-gap-courts-regulators PepsReview en 2026-10-10 GLP-1 lawsuits, Ozempic litigation, NAION, semaglutide safety, tirzepatide, adverse event reporting, pancreatitis, FDA https://pepsreview.com/articles/fda-peptide-crackdown-supply-chain-gaps PepsReview en 2026-10-09 FDA peptide enforcement, peptide warning letters, retatrutide, gray market peptides, peptide supply chain, semaglutide imports, peptide testing https://pepsreview.com/articles/gray-market-semaglutide-buyers-bankrolling-fentanyl-precursor-suppliers PepsReview en 2026-10-09 semaglutide, gray market peptides, fentanyl precursors, GLP-1, research chemicals, peptide safety, counterfeit Ozempic, supply chain